TD Cowen analyst Stacy Ku initiates coverage on BioCryst Pharma (NASDAQ: BCRX) with a Buy rating and a price target ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage